This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

BioProcess International US West

Attendee Deadline to Submit a Poster Abstract

  • 00
    Days
  • 00
    Hrs
  • 00
    Mins
  • 00
    Secs
Delivered as a Hybrid Event
February 27 - March 2, 2023San Diego Convention Center

Joseph Rininger, Ph.D.
Managing Director, Cell and Gene Therapy at Latham Biopharma

Profile

Dr. Rininger possesses over twenty years of experience in basic biomedical research and biopharmaceutical product development, manufacturing and program management with an emphasis on vaccines and gene therapy. Prior to joining Latham Biopharm Group (LBG), he worked at several small and mid-size biotechnology companies, growing into positions of increased responsibility at each organization. As the Senior Director at Protein Sciences Corporation (PSC), Dr. Rininger was the program manager of a BARDA contract for the advanced development and commercialization of Flublok®, the first approved recombinant hemagglutinin-based subunit vaccine for seasonal influenza. This encompassed planning and leading a cross-functional team in the execution of tasks involving all areas of recombinant protein-based vaccine development (process development, formulation development and stability, pre-clinical efficacy and toxicology, quality control/quality systems, process and facility validation, manufacturing process transfer, regulatory affairs and clinical development) and routine government reporting.

Prior to that role, he served as Director of Business Development and worked to secure new biologic contract manufacturing projects, grew an established research product business unit evaluated in- and out-licensing of technology and performed writing and submission of NIH grant funding opportunities. For the contract manufacturing projects, he successfully oversaw project teams for the development of upstream and downstream processes for transfer to cGMP manufacturing of four vaccine candidates and two biologics. In technology licensing and government funding, he licensed the manufacturing technology and supported the regulatory submissions for Glybera, the first AAV gene therapy approved in the western world and was awarded an AAV manufacturing process development project from NIH/NHLBI.

At LBG, Dr. Rininger leads product development engagements with cell and gene therapy companies and service providers to model the cell and gene therapy/viral vector space. He has worked to bring two client AAV programs into the clinic and is actively involved in regulatory interactions. He also supports both commercial and US Government funded development programs as a subject matter expert on vaccine and biopharmaceutical development and program management. Dr. Rininger earned his Ph.D. from Cornell University in Toxicology and a B.S. in Marine Biology with a Concentration in Biotechnology from Fairleigh Dickinson University. He has several awarded and pending patents and is well published in industry and peer-reviewed journals.

Agenda Sessions

  • Key Attributes and Intangible Considerations of Cell and Gene Therapy CDMO Selection by Innovator Companies

    4:00pm
  • Panel Discussion: CGT CDMO Selection and Manufacturing Best Practices

    4:30pm